Joseph Tucker

Enveric Biosciences Advances Non-Hallucinogenic DMT Analog Drug With Promising Preclinical Results

Enveric Biosciences Trims Losses, Eyes Key Drug Approval For Difficult-To-Treat Mental Health Disorders

Enveric Biosciences Out-Licenses Key Program To MycoMedica In $62M Deal

Enveric Biosciences Trims Losses, Eyes Key Drug Approval For Difficult-To-Treat Mental Health Disorders

Enveric Biosciences Out-Licenses Key Program To MycoMedica In $62M Deal

Enveric Biosciences Advances Testing Of Its Non-Hallucinogenic Psychedelic

Psychedelics 2.0: Companies Explore Safer, More Targeted Therapies

Enveric Biosciences Advances Testing Of Its Non-Hallucinogenic Psychedelic

Psychedelics 2.0: Companies Explore Safer, More Targeted Therapies

Non-Hallucinogenic Psychedelic Treatment For Anxiety And Depression In Pre-Clinical Models: Enveric Biosciences' Breakthrough Research

Non-Hallucinogenic Psychedelic Treatment For Mental Health Disorders Shows Potential To Be Dosed Orally

Joseph Tucker Recent News

New Patented Psychedelic Drug Brings Hope For Brain Disorder Therapies

Enveric Biosciences has been granted a U.S. patent for EB-002, enhancing protection for treatments targeting brain neurological disorders, including depression and anxiety.

'Psychedelics-Inspired' Meds For Depression, Anxiety, Addiction Producer Trims Q1 Net Loss YoY, Increases Cash On Hand

Enveric Biosciences reported on Wednesday financial results for the first quarter of 2024 ended March 31, 2024."We believe the first quarter of 2024 was a highly productive period for Enveric as the company continued to advance the development of the lead neuroplastogen drug candidate, EB-003, in preparation for an investigational new drug (IND) application and the expected initiation of a planned clinical development program," Joseph Tucker, Ph.D., director and CEO of Enveric, said. "EB-003 was designed specifically to address this major safety profile deficiency in the first-generation psychedelic approach to treating neuropsychiatric illness, and we are excited to advance its development."

Microdosing For Depression: Psychedelics Biotech Signs $66.5M Non-Binding Deal To Out-License Novel Psilocin Prodrug Candidate

Cannabinoids With Chemotherapy For Breast Cancer: Psychedelics Biotech Inks $61M License Deal For Patented Methods

The news of the licensee deal comes on the heels of the DEA's move to reschedule marijuana, one source of cannabinoids, as a Schedule III controlled substance.

Enveric Completes Manufacturing Of Its Psilocin Prodrug To Supply Drug Material For Completion Of Preclinical Program

Enveric Biosciences (NASDAQ: ENVB) has completed manufacturing of drug material enabling the completion of preclinical work for EB-373 including all bioanalytical method validation, GLP toxicology and GLP safety pharmacology studies.

Enveric Unveils Positive Results From Preclinical Studies Supporting Metabolic Profile Of Its Psilocin Prodrug For Anxiety

Enveric Biosciences (NASDAQ: ENVB) announced successful completion of preclinical absorption, distribution, metabolism, and excretion (ADME) and toxicology studies conforming to earlier positive results fro

Enveric Unveils Positive Results From Animal Studies Of Its Psilocin Prodrug For Anxiety

Enveric Biosciences (NASDAQ: ENVB) announced positive results from pharmacokinetic animal studies demonstrating oral bioavailability, rapid onset of action and systemic clearance, and a more favorable side

Psychedelics Company Takes 'A Key Step' With New Formulation Of Its Psilocin Prodrug For Anxiety

Enveric Biosciences (NASDAQ: ENVB) announced the development of an improved formulation of EB-373 designed to enhance the drug product’s scalability, stability, and delivery for ongoing preclinical studies and planned clinical development.

Enveric Stock Trading Higher On Notice Of Allowance For Patent Application For Its Carboxylated Psilocybin Derivatives

Enveric Biosciences, Inc. (NASDAQ: ENVB) has received a notice of allowance from the United States Patent and Trademark Office (USPTO) for a patent application pertaining to its EVM301 series of molecules being developed as potential treatments for mental health dis

Enveric Stock Soars On Reception Of Notice Of Allowance For Patent Application For Its Psilocin Prodrug Designs

Enveric Biosciences, Inc.

Enveric Releases Paper Detailing The Development Of Novel Psilocin Prodrugs For The Treatment Of Mental Health Disorders

Enveric Biosciences, Inc. (NASDAQ: ENVB) has announced new research results detailing the development of novel psilocin prodrug derivatives targeting treatment of mental health disorders. A manuscript describing the research has been submitted for peer-reviewed publication and is currently

Enveric Bio Stock Spikes 115% After Its Novel Prodrug Of Psilocin Receives Notice Of Allowance From US Patent And Trademark Office

Enveric Biosciences, Inc. (NASDAQ: ENVB) has received a notice of allowance from the United States Patent and Trademark Office for a patent application involving EB-373, th

Enveric Biosciences Reports Q1 2023 Loss, Implements Deep Staff Cuts & Halting Spinoff

Enveric Biosciences, Inc. (NASDAQ: ENVB) released its corporate update and reported financial results for the first quarter of 2023 ending March 31, 2023.

EXCLUSIVE: In Reinventing Mental Health & Next-Gen Psychedelics, 'Access And Clinical Data Are Key'

Experts gathered at the Benzinga Psychedelics Capital Conference in Miami Beach on Thursday where they talked about revolutionizing psychedelic therapy as a promising new approach for treating mental health conditions and how clinical dat

Cannabis For Arthritis: Enveric Biosciences Files Patent On CBD Medication For Osteoarthritis

Psychedelics and cannabinoid neuroscience company Enveric Biosciences (NASDAQ: ENVB) announced the development of two new molecular conjugates for osteoarthritis and other pain indications, which mix CBD with Celecoxib, a generic drug commonly prescribed for osteoarthritis.

Cannabis Movers & Shakers: NORML, TGOD, Enveric Biosciences, Dalwhinnie Enterprises

Texas NORML Director Hired To Oversee State Policy Reform Efforts The National Organization for the Reform of Marijuana Laws (NORML) recently announced that it has tapped Jax Finkel James to its national staff.

Nasdaq Welcomes New Psychedelics Company In $23M M&A Transaction

The psychedelics sector has closed one of its largest M&As since its inception.

Another Psychedelics Company Joins 'Exclusive Nasdaq Group' With Enveric's Acquisition Of MagicMed Industries

CBD-focused biotechnology company Enveric Biosciences (NASDAQ: ENVB) confirmed Monday it will acquire psychedelics company MagicMed Industries in an all-stock deal.

Video: Experts Discuss Use of Psychedelics in Mental Health Settings

The psychedelics industry has started to gain serious traction and is attracting lots of attention these days. However, what many people may not know is that the sector has been up and running for decades, with various psychedelic substances already being used for medical treatment.

4 Psychedelics Experts On Adoption In Mainstream Medicine: 'A Mental Health Revolution'

The use of psychedelics for medical treatment is achieving a new sense of gravitas, according to the guest panelists at Benzinga's latest Cannabis Capital Conference.